Cargando…

Incidence of type 2 diabetes in familial combined hyperlipidemia

OBJECTIVE: Familial combined hyperlipidemia (FCHL) is common among survivors of a premature myocardial infarction. FCHL patients are characterized by visceral obesity, fatty liver, and insulin resistance. The aim of the present study was to determine the incidence and determinants of type 2 diabetes...

Descripción completa

Detalles Bibliográficos
Autores principales: Brouwers, Martijn C G J, de Graaf, Jacqueline, Simons, Nynke, Meex, Steven, ten Doeschate, Sophie, van Heertum, Shadana, Heidemann, Britt, Luijten, Jim, de Boer, Douwe, Schaper, Nicolaas, Stehouwer, Coen D A, van Greevenbroek, Marleen M J
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7103854/
https://www.ncbi.nlm.nih.gov/pubmed/32193201
http://dx.doi.org/10.1136/bmjdrc-2019-001107
_version_ 1783512125975560192
author Brouwers, Martijn C G J
de Graaf, Jacqueline
Simons, Nynke
Meex, Steven
ten Doeschate, Sophie
van Heertum, Shadana
Heidemann, Britt
Luijten, Jim
de Boer, Douwe
Schaper, Nicolaas
Stehouwer, Coen D A
van Greevenbroek, Marleen M J
author_facet Brouwers, Martijn C G J
de Graaf, Jacqueline
Simons, Nynke
Meex, Steven
ten Doeschate, Sophie
van Heertum, Shadana
Heidemann, Britt
Luijten, Jim
de Boer, Douwe
Schaper, Nicolaas
Stehouwer, Coen D A
van Greevenbroek, Marleen M J
author_sort Brouwers, Martijn C G J
collection PubMed
description OBJECTIVE: Familial combined hyperlipidemia (FCHL) is common among survivors of a premature myocardial infarction. FCHL patients are characterized by visceral obesity, fatty liver, and insulin resistance. The aim of the present study was to determine the incidence and determinants of type 2 diabetes (T2D) in a longitudinal cohort of FCHL pedigrees. RESEARCH DESIGN AND METHODS: FCHL patients, their unaffected relatives and spouses included in our baseline cohort in 1998–2005 (n=596) were re-invited to determine the incidence of self-reported T2D (that was confirmed by medical records), used as the primary outcome measure. The Fatty Liver Index (FLI) and Homeostasis Model Assessment Insulin Resistance (HOMA2-IR) were used as markers of fatty liver and insulin resistance, respectively. A subset of the original cohort underwent ultrasound of the liver, and subcutaneous and visceral fat in 2002–2005 (n=275; ‘ultrasound subcohort’). RESULTS: Follow-up data (median: 15 years) was acquired for 76%. The incidence rate of T2D was significantly higher in FCHL patients compared with spouses (19.2 per 1000 person-years vs 2.8 per 1000 person-years; HR : 6.3, 95% CI: 2.4 to 16.8), whereas no differences were observed between unaffected relatives and spouses (HR: 0.9, 95% CI: 0.3 to 2.6). Cox’s proportional hazard regression analyses showed that baseline HOMA2-IR and FLI≥60, but not waist circumference, BMI, or the FCHL affected state, were independently associated with incident T2D. Similar results were obtained in the ultrasound subcohort (median follow-up: 11 years), in which baseline HOMA2-IR and fatty liver (assessed by ultrasound) were independently associated with incident T2D. CONCLUSION: This study further corroborates the suggestion that the liver plays a central role in the pathogenesis of cardiometabolic complications in FCHL. It supports periodical screening for T2D in this high-risk population.
format Online
Article
Text
id pubmed-7103854
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher BMJ Publishing Group
record_format MEDLINE/PubMed
spelling pubmed-71038542020-03-31 Incidence of type 2 diabetes in familial combined hyperlipidemia Brouwers, Martijn C G J de Graaf, Jacqueline Simons, Nynke Meex, Steven ten Doeschate, Sophie van Heertum, Shadana Heidemann, Britt Luijten, Jim de Boer, Douwe Schaper, Nicolaas Stehouwer, Coen D A van Greevenbroek, Marleen M J BMJ Open Diabetes Res Care Cardiovascular and Metabolic Risk OBJECTIVE: Familial combined hyperlipidemia (FCHL) is common among survivors of a premature myocardial infarction. FCHL patients are characterized by visceral obesity, fatty liver, and insulin resistance. The aim of the present study was to determine the incidence and determinants of type 2 diabetes (T2D) in a longitudinal cohort of FCHL pedigrees. RESEARCH DESIGN AND METHODS: FCHL patients, their unaffected relatives and spouses included in our baseline cohort in 1998–2005 (n=596) were re-invited to determine the incidence of self-reported T2D (that was confirmed by medical records), used as the primary outcome measure. The Fatty Liver Index (FLI) and Homeostasis Model Assessment Insulin Resistance (HOMA2-IR) were used as markers of fatty liver and insulin resistance, respectively. A subset of the original cohort underwent ultrasound of the liver, and subcutaneous and visceral fat in 2002–2005 (n=275; ‘ultrasound subcohort’). RESULTS: Follow-up data (median: 15 years) was acquired for 76%. The incidence rate of T2D was significantly higher in FCHL patients compared with spouses (19.2 per 1000 person-years vs 2.8 per 1000 person-years; HR : 6.3, 95% CI: 2.4 to 16.8), whereas no differences were observed between unaffected relatives and spouses (HR: 0.9, 95% CI: 0.3 to 2.6). Cox’s proportional hazard regression analyses showed that baseline HOMA2-IR and FLI≥60, but not waist circumference, BMI, or the FCHL affected state, were independently associated with incident T2D. Similar results were obtained in the ultrasound subcohort (median follow-up: 11 years), in which baseline HOMA2-IR and fatty liver (assessed by ultrasound) were independently associated with incident T2D. CONCLUSION: This study further corroborates the suggestion that the liver plays a central role in the pathogenesis of cardiometabolic complications in FCHL. It supports periodical screening for T2D in this high-risk population. BMJ Publishing Group 2020-03-18 /pmc/articles/PMC7103854/ /pubmed/32193201 http://dx.doi.org/10.1136/bmjdrc-2019-001107 Text en © Author(s) (or their employer(s)) 2020. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ. http://creativecommons.org/licenses/by-nc/4.0/This is an open access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited, appropriate credit is given, any changes made indicated, and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/.
spellingShingle Cardiovascular and Metabolic Risk
Brouwers, Martijn C G J
de Graaf, Jacqueline
Simons, Nynke
Meex, Steven
ten Doeschate, Sophie
van Heertum, Shadana
Heidemann, Britt
Luijten, Jim
de Boer, Douwe
Schaper, Nicolaas
Stehouwer, Coen D A
van Greevenbroek, Marleen M J
Incidence of type 2 diabetes in familial combined hyperlipidemia
title Incidence of type 2 diabetes in familial combined hyperlipidemia
title_full Incidence of type 2 diabetes in familial combined hyperlipidemia
title_fullStr Incidence of type 2 diabetes in familial combined hyperlipidemia
title_full_unstemmed Incidence of type 2 diabetes in familial combined hyperlipidemia
title_short Incidence of type 2 diabetes in familial combined hyperlipidemia
title_sort incidence of type 2 diabetes in familial combined hyperlipidemia
topic Cardiovascular and Metabolic Risk
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7103854/
https://www.ncbi.nlm.nih.gov/pubmed/32193201
http://dx.doi.org/10.1136/bmjdrc-2019-001107
work_keys_str_mv AT brouwersmartijncgj incidenceoftype2diabetesinfamilialcombinedhyperlipidemia
AT degraafjacqueline incidenceoftype2diabetesinfamilialcombinedhyperlipidemia
AT simonsnynke incidenceoftype2diabetesinfamilialcombinedhyperlipidemia
AT meexsteven incidenceoftype2diabetesinfamilialcombinedhyperlipidemia
AT tendoeschatesophie incidenceoftype2diabetesinfamilialcombinedhyperlipidemia
AT vanheertumshadana incidenceoftype2diabetesinfamilialcombinedhyperlipidemia
AT heidemannbritt incidenceoftype2diabetesinfamilialcombinedhyperlipidemia
AT luijtenjim incidenceoftype2diabetesinfamilialcombinedhyperlipidemia
AT deboerdouwe incidenceoftype2diabetesinfamilialcombinedhyperlipidemia
AT schapernicolaas incidenceoftype2diabetesinfamilialcombinedhyperlipidemia
AT stehouwercoenda incidenceoftype2diabetesinfamilialcombinedhyperlipidemia
AT vangreevenbroekmarleenmj incidenceoftype2diabetesinfamilialcombinedhyperlipidemia